For patients with clinical or biochemical findings suspicious for prostate cancer, gallium-68 (68Ga)-labeled prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) has high accuracy for detecting prostate cancer, according to a review recently published in the American Journal of Roentgenology.
Swayamjeet Satapathy, M.B.B.S., from the Post Graduate Institute of Medical Education and Research in Chandigarh, India, and colleagues conducted a systematic review to assess the diagnostic performance of 68Ga-PSMA PET/CT in the initial detection of prostate cancer in patients with clinical or biochemical findings suspicious for the cancer. Histopathology results were used as the reference standard. A bivariate random-effects meta-analysis was used to generate pooled estimates of diagnostic test accuracy. Data were included from seven studies with 389 patients.
The researchers found that the pooled sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio were 0.97, 0.66, 2.86, and 0.05, respectively, for the initial diagnosis of prostate cancer using 68Ga-PSMA PET/CT. High accuracy was demonstrated with the test, with an area under the summary receiver operating characteristic curve of 0.91
“68Ga-PSMA PET/CT has a potential application as a rule-out test in patients with clinical or biochemical findings suspicious for prostate cancer, and its use can avoid unnecessary biopsies in this population,” the authors write. “Larger prospective studies comparing its diagnostic performance with that of multiparametric magnetic resonance imaging in this setting are urgently needed.”